Premium
Development and validation of a high‐performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP‐18770 in human plasma and its application in a clinical pharmacokinetic study
Author(s) -
Sala Federica,
Marangon Elena,
Bagnati Renzo,
Livi Valeria,
Cereda Roberta,
D'Incalci Maurizio,
Zucchetti Massimo
Publication year - 2010
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/jms.1842
Subject(s) - chemistry , chromatography , protein precipitation , pharmacokinetics , tandem mass spectrometry , boronic acid , proteasome inhibitor , liquid chromatography–mass spectrometry , selected reaction monitoring , high performance liquid chromatography , mass spectrometry , coefficient of variation , detection limit , proteasome , pharmacology , biochemistry , combinatorial chemistry , medicine
CEP‐18770, [(1 R )‐1‐{[(2 S ,3 R )‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) method was developed and validated to measure the drug in human plasma, based on simple protein precipitation with acetonitrile after the addition of irbesartan as internal standard. The method requires a small volume of sample (100 µl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise and accurate, with overall precision, expressed as coefficient of variation (CV%), always < 10.0%, accuracy in the range 93.8–107.7% and high recovery, close to 100%. The limit of detection is 0.01 ng/ml and the lower limit of quantitation (LLOQ) is 0.20 ng/ml. The assay was validated in the range from the LLOQ up to 50.00 ng/ml. This is the first method developed and validated for analyzing a proteasome inhibitor with a boronic‐acid‐based structure in human plasma. The method was successfully applied to study the pharmacokinetics of CEP‐18770 in cancer patients with solid tumors or multiple myeloma who had received the drug as a short intravenous bolus during the initial Phase I trial. Copyright © 2010 John Wiley & Sons, Ltd.